medigraphic.com
ISSN 0016-3813 (Impreso)

2019, Número 4

<< Anterior Siguiente >>

Gac Med Mex 2019; 155 (4)


Consenso multidisciplinario de diagnóstico y tratamiento del dolor neuropático periférico y localizado en México

Lara-Solares A, Mayoral-Rojals V, Guillén-Núñez MR, Villafaña-Tello JJS, Cantú-Brito C, Genis-Rondero MÁ, Nader-Kawachi JA, Tito-Hernández H, Salado-Ávila MM, De la Paz-Lozano JA, Hernández-Ortiz A, Flores-Cantisani JA, Leyva-Rendón A, Hernández-Santos KF

Idioma: Español
Referencias bibliográficas: 33
Paginas: 428-435
Archivo PDF: 159.17 Kb.


RESUMEN

El dolor neuropático es una entidad que provoca discapacidad al paciente y su diagnóstico y tratamiento es un reto para los médicos. En un porcentaje importante de pacientes afectados, el dolor neuropático se presenta circunscrito a un dermatoma o a una región concreta del cuerpo, denominándose en ese caso dolor neuropático localizado. No existen guías clínicas mexicanas que postulen recomendaciones para el diagnóstico y tratamiento del dolor neuropático localizado en nuestra población. En este artículo se exponen las recomendaciones de un consenso multidisciplinario realizado con especialistas de distintas áreas implicadas en el diagnóstico y tratamiento de este tipo de pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mick G, Baron R, Finnerup NB, Hans G, Kern KU, Brett B, et al. What is localized neuropathic pain?A first proposal to characterize and define a widely used term. Pain Manag. 2012;2:71-77.

  2. Golan-Vered Y, Pud D. Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel. Pain Pract. 2013;13:46-52.

  3. Acevedo JC, Amaya A, Casasola-Ode L, Chinchilla N, De-Giorgis M, Florez S, et al. Guidelines for the diagnosis and management of neuropathic pain:consensus of a group of Latin American experts. J Pain Palliat Care Pharmacother.2009;23:261-281.

  4. Okoli C, Pawlowski S. The Delphi method as a research tool:an example, design considerations and applications. Inform Manag. 2004;42:15-29.

  5. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, HaanpääML, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update. Mayo Clin Proc. 2010;85:S3-S14.

  6. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain:redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.

  7. Gilron I, Baron R, Jensen T. Neuropathic pain:principles of diagnosis and treatment. Mayo Clin Proc. 2015;90:532-545.

  8. Covarrubias-Gómez A, Guevara-López UM, Cantú-Brito C, Nuche-Cabrera E, Guajardo-Rosas JA. Recomendaciones de práctica clínica para el manejo del dolor neuropático:Grupo de interés en dolor neuropático de la Asociación Mexicana para el Estudio y Tratamiento del Dolor. Rev Mex Anestesiol. 2015;38:264-276.

  9. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain:evidence-based recommendations. Pain. 2007;132:237-251.

  10. Pickering G, Martin E, Tiberghien F, Delorme C, Mick G. Localized neuropathic pain:an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709-2718.

  11. Van-Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population:a systematic review of epidemiological studies. Pain. 2014;155:654-662.

  12. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain:how far have we come?. Diabetes Care. 2008;31:S255-S261.

  13. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed. 2007;9:36.

  14. Backonja MM. Defining neuropathic pain. Anesth Analg. 2003;97:785-790.

  15. Montero-Homs J, Gutiérrez-Rivas E, Pardo-Fernández J, Navarro-Darder C, PREVADOL. Epidemiological study of prevalence, incidence and neuropathic pain characterization in neurology units. PREVADOL study. Neurologia. 2005;20:385-389.

  16. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life:a prospective representative survey. Acta Anaesthesiol Scand. 2008;52:132-136.

  17. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ. The prevalence of neuropathic pain:clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10:586-593.

  18. Pérez C, Saldaña MT, Navarro A, Vilardaga I, Rejas J. Prevalence and characterization of neuropathic pain in a primary-care setting in Spain:a cross-sectional, multicentre, observational study. Clin Drug Investig. 2009;29:441-450.

  19. Cruciani RA, Nieto MJ. Physiopathology and treatment of neuropathic pain:recent developments. Rev Soc Esp Dolor. 2006;13:312-327.

  20. Woolf CJ, Mannion RJ. Neuropathic pain:aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959-1964.

  21. DualéC, Ouchchane L, Schoeffler P, EDONIS Investigating Group, Dubray C. Neuropathic aspects of persistent postsurgical pain:a French multicenter survey with a 6-month prospective follow-up. J Pain. 2014;15:24.e1-24.e20.

  22. Mick G, Baron R, Correa-Illanes G, Hans G, Mayoral V, Frías X, et al. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice?Development of a screening tool based on IASP criteria. Curr Med Res Opin. 2014;30:1357-1366.

  23. Mayoral V, Pérez-Hernández C, Muro I, Leal A, Villoria J, Esquivias A. Diagnostic accuracy of an identification tool for localized neuropathic pain based on the IASP criteria. Curr Med Res Opin. 2018;34:1465-1473.

  24. Buonocore M. Unilateral peripheral neuropathic pain:The role of neurodiagnostic skin biopsy. World J Clin Cases. 2014;2:27-31.

  25. Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-912.

  26. Zakrewska JM, Padfield D. The Patient's Journey Through Trigeminal Neuralgia. IASP Pain Clinical Updates. 2014;22:1-8.

  27. Löfgren M, Norrbrink C. “But I know what works“:patients'experience of spinal cord injury neuropathic pain management. Disabil Rehabil. 2012;34:2139-2147.

  28. Attal N, Cruccu G, Baron R, HaanpääM, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision. Eur J Neurol. 2010;17:1113-1188.

  29. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults:a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-173.

  30. Amescua-Garcia C, Colimon F, Guerrero C, Jreige Iskandar A, Berenguel-Cook M, Bonilla P, et al. Most relevant neuropathic pain treatment and chronic low back pain management guidelines:a change pain Latin America advisory panel consensus. Pain Med. 2018;19:460-470.

  31. Cruccu G, Truini A. A review of neuropathic pain:from guidelines to clinical practice. Pain Ther. 2017;6:35-42.

  32. Allegri M, Baron R, Hans G, Correa-Illanes G, Mayoral-Rojals V, Mick G, et al. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32:377-384.

  33. Neuropathic pain overview. Reino Unido:National Institute for Health and Care Excellence;2018.




2020     |     www.medigraphic.com